---
title: "Stakeholder preferences for long-acting injectables in tuberculosis treatment and prevention"
id: "medrxiv-7-stakeholder-perspectives-and-preferences-for-long-acting-injectables-for"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-stakeholder-perspectives-and-preferences-for-long-acting-injectables-for"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1?rss=1"
published_at: "2026-11-09T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Stakeholder preferences for long-acting injectables in tuberculosis treatment and prevention
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-stakeholder-perspectives-and-preferences-for-long-acting-injectables-for
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1?rss=1)
- **Published At:** 2026-11-09T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study assessed acceptability and preferences for **long-acting injectables** (**LAIs**) for **tuberculosis** (TB) treatment and prevention across multiple World Health Organization regions using a sequential explanatory mixed-methods design. - Two online surveys were deployed: Survey A targeted TB programme managers, civil society and healthcare workers; Survey B targeted community members and people affected by TB. - Purposive sampling invited survey respondents to follow-up focus group discussions (FGDs) to explore the quantitative findings qualitatively. - Analyses included descriptive statistics, ordinal logistic regression with stepwise AIC selection, and one-sample proportion tests for survey data; FGDs were analysed with modified framework analysis. - Total participants numbered 310 (102 in Survey A; 208 in Survey B), and 83% (n=256) overall indicated a preference for **LAIs** over standard oral TB treatment. - For a hypothetical three-month regimen (one month oral then two monthly visits with injections), 69% preferred one-injection-per-visit and 80% preferred two-injections-per-visit compared with six months of daily oral therapy. - For TB prevention, 79% of respondents preferred a single injection over one month of oral preventive therapy. - Interest in **LAIs** was lower among participants with lived experience of TB; FGDs suggested prior negative experiences with injectable formulations and concerns about side effects influenced that finding. - The authors reported ethical approvals and funding sources. The paper is a medRxiv preprint and has not undergone peer review. - The manuscript includes summary findings and illustrative quotations; additional methodological and dosing specifics for potential LAI products were not reported in the abstract and would require consultation of full text or supplementary materials.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=hH.TC4HzloiPzXYvz14vn8ZsywJjbCrtsxQhtEaUBo0-1794265746.3030188-1.2.1.1-P0llZLCsg8duLsR1Rf8wMYDtzs7tQ1utSGEN72yA98SxoQEQDefT2yM2qVO.IWp9) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Stakeholder perspectives and preferences for long-acting injectables for tuberculosis treatment and prevention: a multi-regional mixed-methods study [ View ORCID Profile](http://orcid.org/0000-0001-7720-3349)Chaelin Kim, [ View ORCID Profile](http://orcid.org/0009-0009-2036-2272)Erin V. McConnell, [ View ORCID Profile](http://orcid.org/0000-0002-6136-206X)Samuel G. Schumacher, [ View ORCID Profile](http://orcid.org/0000-0001-8798-7909)Dennis Falzon, [ View ORCID Profile](http://orcid.org/0009-0003-0516-2332)Medea Gegia, [ View ORCID Profile](http://orcid.org/0009-0007-3205-6761)Lusiana Aprilawati, [ View ORCID Profile](http://orcid.org/0009-0000-9184-7263)Jimmy Galarza, [ View ORCID Profile](http://orcid.org/0009-0008-1223-7845)Edna Tembo, [ View ORCID Profile](http://orcid.org/0009-0001-3785-4208)Lesia Tonkonoh, [ View ORCID Profile](http://orcid.org/0000-0002-7263-9896)Gwenan M Knight, [ View ORCID Profile](http://orcid.org/0000-0001-6199-0931)C Finn McQuaid, [ View ORCID Profile](http://orcid.org/0000-0001-6658-0325)Fuad Mirzayev, [ View ORCID Profile](http://orcid.org/0000-0001-8556-1744)Nora West doi: https://doi.org/10.64898/2026.11.06.26367430 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Chaelin Kim 1 London School of Hygiene & Tropical Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Chaelin%2BKim%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kim%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChaelin%2BKim%2B) * [ORCID record for Chaelin Kim](http://orcid.org/0000-0001-7720-3349 "Open in new tab") * For correspondence: ckim0509@gmail.com Erin V. McConnell 2 Treatment Action Group; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Erin%2BV.%2BMcConnell%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=McConnell%20EV&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AErin%2BV.%2BMcConnell%2B) * [ORCID record for Erin V. McConnell](http://orcid.org/0009-0009-2036-2272 "Open in new tab") Samuel G. Schumacher 3 World Health Organization; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Samuel%2BG.%2BSchumacher%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Schumacher%20SG&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASamuel%2BG.%2BSchumacher%2B) * [ORCID record for Samuel G. Schumacher](http://orcid.org/0000-0002-6136-206X "Open in new tab") Dennis Falzon 3 World Health Organization; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dennis%2BFalzon%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Falzon%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADennis%2BFalzon%2B) * [ORCID record for Dennis Falzon](http://orcid.org/0000-0001-8798-7909 "Open in new tab") Medea Gegia 3 World Health Organization; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Medea%2BGegia%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gegia%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMedea%2BGegia%2B) * [ORCID record for Medea Gegia](http://orcid.org/0009-0003-0516-2332 "Open in new tab") Lusiana Aprilawati 4 Jaringan Peduli TB Indonesia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lusiana%2BAprilawati%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Aprilawati%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALusiana%2BAprilawati%2B) * [ORCID record for Lusiana Aprilawati](http://orcid.org/0009-0007-3205-6761 "Open in new tab") Jimmy Galarza 5 University of Texas Health Science Center at Houston; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jimmy%2BGalarza%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Galarza%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJimmy%2BGalarza%2B) * [ORCID record for Jimmy Galarza](http://orcid.org/0009-0000-9184-7263 "Open in new tab") Edna Tembo 6 Coalition of Women Living with HIV and AIDS; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Edna%2BTembo%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tembo%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEdna%2BTembo%2B) * [ORCID record for Edna Tembo](http://orcid.org/0009-0008-1223-7845 "Open in new tab") Lesia Tonkonoh 7 TB Europe Coalition; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lesia%2BTonkonoh%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tonkonoh%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALesia%2BTonkonoh%2B) * [ORCID record for Lesia Tonkonoh](http://orcid.org/0009-0001-3785-4208 "Open in new tab") Gwenan M Knight 1 London School of Hygiene & Tropical Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Gwenan%2BM%2BKnight%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Knight%20GM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGwenan%2BM%2BKnight%2B) * [ORCID record for Gwenan M Knight](http://orcid.org/0000-0002-7263-9896 "Open in new tab") C Finn McQuaid 1 London School of Hygiene & Tropical Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=C%2BFinn%2BMcQuaid%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=McQuaid%20CF&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AC%2BFinn%2BMcQuaid%2B) * [ORCID record for C Finn McQuaid](http://orcid.org/0000-0001-6199-0931 "Open in new tab") Fuad Mirzayev 3 World Health Organization; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Fuad%2BMirzayev%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mirzayev%20F&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AFuad%2BMirzayev%2B) * [ORCID record for Fuad Mirzayev](http://orcid.org/0000-0001-6658-0325 "Open in new tab") Nora West 8 University of California, San Francisco * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nora%2BWest%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=West%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANora%2BWest%2B) * [ORCID record for Nora West](http://orcid.org/0000-0001-8556-1744 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1340577/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1340577/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1340577/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1340577/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1340577/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1340577/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objective: To assess stakeholder acceptability of and preferences for long-acting injectables (LAIs) for tuberculosis (TB) treatment and prevention across World Health Organization regions to inform product development and implementation. Methods: We conducted a sequential explanatory mixed-methods study of survey data and qualitative focus group discussions (FGDs). Online surveys assessed perceptions and acceptance of LAIs among two groups: TB programme managers, civil society members and healthcare workers (Survey A), and community members and persons affected by TB (Survey B). Using purposive sampling, survey participants were invited to join FGDs to explore survey findings. Survey data were analysed using descriptive statistics, ordinal logistic regression with stepwise AIC selection, and one-sample proportion tests. FGD transcripts were analysed using modified framework analysis. Findings: Among 310 participants (102 Survey A; 208 Survey B), 83% (n=256) favoured LAIs over standard oral TB treatment. Compared with six months of daily oral treatment, 69% preferred a three-month regimen comprising one month of daily oral treatment followed by four injections per monthly visit for two months, while 80% preferred the corresponding regimen with two injections per visit. For prevention, 79% preferred a single injection over one month of oral treatment. In Survey B, interest varied according to lived TB experience, with FGDs suggesting that previous negative experiences with injectables may have contributed to this variation. Conclusion: Interest in LAIs for TB treatment and prevention was high, but lower among participants with lived TB experience. Product development and implementation should address concerns about injectables and side effects while preserving patient choice and agency. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study received ethical approval from the WCG Institutional Review Board (IRB Protocol #: 20252075) and the London School of Hygiene & Tropical Medicine Research Ethics Committee (LSHTM Ethics Ref: 33795). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Summary findings and illustrative quotations are included in the manuscript and supplementary material. ## Funder Information Declared Gates Foundation, Investment ID INV-086496 Unitaid, Enabler Grant 2023-2025 No 75327 Medical Research Council, Grant number MR/W006677/1 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.09.26367184v1 "Longitudinal Investigation of Autonomic Symptoms in Biologically Confirmed \(SAA+\) Parkinson's Disease")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.07.26367252v1 "Functional analysis enables reclassification of SCN1A missense variants of uncertain significance in epilepsy") Posted November 09, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/09/2026.11.06.26367430.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/09/2026.11.06.26367430.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Stakeholder perspectives and preferences for long-acting injectables for tuberculosis treatment and prevention: a multi-regional mixed-methods study Chaelin Kim, Erin V. McConnell, Samuel G. Schumacher, Dennis Falzon, Medea Gegia, Lusiana Aprilawati, Jimmy Galarza, Edna Tembo, Lesia Tonkonoh, Gwenan M Knight, C Finn McQuaid, Fuad Mirzayev, Nora West medRxiv 2026.11.06.26367430; doi: https://doi.org/10.64898/2026.11.06.26367430 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.06.26367430v1%26text%3DStakeholder%2520perspectives%2520and%2520preferences%2520for%2520long-acting%2520injectables%2520for%2520tuberculosis%2520treatment%2520and%2520prevention%253A%2520a%2520multi-regional%2520mixed-methods%2520study "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.06.26367430v1%26t%3DStakeholder%2520perspectives%2520and%2520preferences%2520for%2520long-acting%2520injectables%2520for%2520tuberculosis%2520treatment%2520and%2520prevention%253A%2520a%2520multi-regional%2520mixed-methods%2520study "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.06.26367430v1%26title%3DStakeholder%2520perspectives%2520and%2520preferences%2520for%2520long-acting%2520injectables%2520for%2520tuberculosis%2520treatment%2520and%2520prevention%253A%2520a%2520multi-regional%2520mixed-methods%2520study%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.06.26367430v1%26title%3DStakeholder%2520perspectives%2520and%2520preferences%2520for%2520long-acting%2520injectables%2520for%2520tuberculosis%2520treatment%2520and%2520prevention%253A%2520a%2520multi-regional%2520mixed-methods%2520study "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.06.26367430v1&count=horizontal&via=&text=Stakeholder%20perspectives%20and%20preferences%20for%20long-acting%20injectables%20for%20tuberculosis%20treatment%20and%20prevention%3A%20a%20multi-regi
## Related Clinical Research

- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Transcriptional Remodeling in Severe Undernutrition During Latent TB Fails to Consistently Predict](https://medichelpline.com/clinical-feed/biorxiv-0-distinct-transcriptional-remodeling-of-immune-and-metabolic-pathways-in-severe.md)
- [Mechanistic Multiclass Model of Vaccine-Induced Humoral Response](https://medichelpline.com/clinical-feed/biorxiv-3-a-multiclass-mechanistic-model-of-vaccine-induced-humoral-response.md)
- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)
- [Bayesian latent class analysis of pediatric tuberculosis diagnostics in Kenya](https://medichelpline.com/clinical-feed/medrxiv-10-using-bayesian-latent-class-models-to-evaluate-tuberculosis-diagnostics-in-a.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.